These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 11929080)

  • 21. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
    Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
    Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer.
    Ozata M; Suzuki S; Miyamoto T; Liu RT; Fierro-Renoy F; DeGroot LJ
    J Clin Endocrinol Metab; 1994 Jul; 79(1):98-105. PubMed ID: 8027262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
    van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
    Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer.
    Zhang HS; Wang RJ; Fu QF; Gao S; Sun BT; Sun H; Ma QJ
    Asian Pac J Cancer Prev; 2014; 15(24):10905-9. PubMed ID: 25605199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
    Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
    Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
    J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up of differentiated thyroid cancer.
    Pacini F
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
    Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of distant metastasis at the time of ablation in children with differentiated thyroid cancer: the value of pre-ablation stimulated thyroglobulin.
    Liu L; Huang F; Liu B; Huang R
    J Pediatr Endocrinol Metab; 2018 Jul; 31(7):751-756. PubMed ID: 29953410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
    Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
    Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.